C. Laurencot

发表

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

S. Rosenberg, R. Morgan, J. Yang, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.

M. Merino, S. Rosenberg, R. Morgan, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Different Adjuvanticity of Incomplete Freund's Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine

S. Rosenberg, J. Yang, N. Restifo, 2010, Journal of immunotherapy.

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

S. Rosenberg, D. Citrin, J. Yang, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

S. Steinberg, S. Rosenberg, D. Citrin, 2011, Clinical Cancer Research.

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

M. Merino, S. Rosenberg, R. Morgan, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Tongguang Wang, Dolores J. Schendel, Richard A. Morgan, 2013, Journal of immunotherapy.

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development

L K Pannell, L. Pannell, K. Gustafson, 1997, Antimicrobial agents and chemotherapy.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

J. Mascola, T. Pierson, C. Andrews, 2017, The Lancet.

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

J. Mascola, A. Namboodiri, R. Koup, 2018, PLoS medicine.

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.

J. Mascola, A. Namboodiri, R. Koup, 2019, The lancet. HIV.

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

S. Rosenberg, D. Citrin, J. Yang, 2010, Clinical Cancer Research.

regression and targets normal tissues expressing cognate antigen Gene therapy with human and mouse T-cell receptors mediates cancer

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009 .

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

W. Wilson, S. Rosenberg, R. Morgan, 2012, Blood.

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114: A Phase 1 Trial of a Therapeutic Monoclonal Antibody Targeting Ebola Virus Glycoprotein

J. Mascola, R. Koup, N. Sullivan, 2019 .

Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines

R. Shoemaker, G. Scheffer, R. Scheper, 1997, International journal of cancer.

Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP.

R. Shoemaker, W. Walther, G. Scheffer, 1997, Journal of the National Cancer Institute.

Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells.

C. Laurencot, K. A. Kennedy, 1995, Oncology research.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009, Blood.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

M. Raffeld, S. Rosenberg, R. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Seth M Steinberg, S. Steinberg, S. Rosenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

J. Mascola, R. Koup, C. Andrews, 2019, The Lancet.

Regulatory aspects for translating gene therapy research into the clinic.

C. Laurencot, Sheryl Ruppel, 2009, Methods in molecular biology.

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

J. Mascola, R. Koup, J. Casazza, 2022, Nature Medicine.

Nonclinical Testing for Oncology Biologic Products

D. Roy, C. Laurencot, P. Andrews, 2004 .

Inhibitors of intracellular pH regulation induce cisplatin resistance in EMT6 mouse mammary tumor cells.

C. Laurencot, P. Andrews, K. A. Kennedy, 1995, Oncology research.

Transitioning trauma research: Navigating the regulatory requirements for medical product development.

C. Laurencot, W. Dean, Natalie M Klein, 2016, The journal of trauma and acute care surgery.

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

S. Rosenberg, R. Morgan, J. Yang, 2012, Blood.